Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2016

View Archived Issues

Prexton Therapeutics starts phase I trial of Parkinson's disease candidate PXT-002331

Bristol-Myers Squibb offers overview of fourth quarter 2015

Genetic inhibition of JNK3 reduces the burden of illness in SMA

Anti-RSPO antibodies show potential for the development of cancer therapies

Development Center for Biotechnology and DCB-USA LLC patent B-Raf and C-Raf inhibitors

Gruenenthal describes PDE4B inhibitors

OptiNose announces pipeline project to evaluate unique nasal drug delivery technology

The Trinity College and InvivoGen divulge NOD1 agonists

Aduro Biotech receives clinical development milestone payments from Janssen

ARIAD receives FDA clearance to begin clinical development of AP-32788

Tenax updates status of ongoing phase III trial of levosimendan in cardiac surgery

Dickkopf-3 identified as a promoter of renal atrophy and fibrosis

Daiichi Sankyo presents accomplishments of third quarter of fiscal 2015

Matinas BioPharma cleared to initiate phase I clinical study of MAT-2501

BMS and Pfizer license Japanese rights to anticoagulant antidote

Transition Therapeutics reports phase II results for oxyntomodulin analogue TT-401

Astellas to codevelop CLINO's gene therapy candidate for retinitis pigmentosa

Mission Therapeutics raises funding to develop deubiquitinating enzyme modulators

Ziarco starts phase IIa trial of ZPL-389 in psoriasis

Extracellular delivery of anticancer agents achieved with intratumoral nanocarrier drug depots

FDA awards fast track designation to PTI-428 for cystic fibrosis

Ryanodex earns FDA fast track designation for exertional heat stroke

Phase IIa topline results for AIR-001 in HFpEF; new HFN-supported study planned

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...